AMENDMENT

In the Claims

Please cancel Claims 7 and 15.

Please enter the following amendments.

B1

1. (Amended) A method for detecting the activity of a compound, comprising,

a) adding to a first cell culture a composition comprising a compound with an unknown effect on inflammation;

b) adding a stimulatory agent to the first cell culture and to a second cell culture;

c) measuring an amount of secreted determinant of inflammation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF-α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture to the amount of determinant from the second cell culture.

2. (Amended) The method of Claim 1, wherein b) adding a stimulatory agent to the first cell culture precedes a) the adding of a composition with an unknown effect on inflammation to the first cell culture.

3. (Amended) The method of Claim 1, wherein a) adding a composition comprising a compound with an unknown effect on inflammation to the first cell culture; and b) adding a stimulatory agent to the first cell culture, occur simultaneously.

10. (Amended) A method for detecting compositions that effect glycated protein accumulation, comprising,

a) adding to a first cell culture a composition comprising a compound with an unknown effect on glycated protein accumulation;

b) adding a glycated protein to the first cell culture and to a second cell culture;

c) measuring the amount of secreted determinant of glycated protein accumulation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture with the amount of the determinant from cells from the second cell culture.

11. (Amended) The method of Claim 10, wherein b) adding a glycated protein to a first cell culture precedes a) the adding of a composition with unknown effects on glycated protein production to cells.

12. (Amended) The method of Claim 10, wherein a) adding a compound with unknown effects on glycated protein production and b) adding a glycated protein to a first cell culture occur simultaneously.

B3

23. (Amended) A method of treating inflammation, comprising administering to a human or animal an effective amount of a composition comprising at least one compound capable of effecting glycated protein accumulation, for the treatment of inflammation-induced diseases, wherein the effect on glycated protein accumulation is determined by:

a) adding to a first cell culture a composition comprising a compound with an unknown effect on glycated protein accumulation;

b) adding a stimulatory agent to the first cell culture and to a second cell culture;

c) measuring an amount of secreted determinant of inflammation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF-α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture to the amount of determinant from the second cell culture.

B4

25. (New) The method of Claim 23, wherein the composition is administered in a pharmaceutically acceptable carrier.

26. (New) The method of Claim 1, further comprising culturing the cells for a predetermined amount of time after adding the stimulatory agent.

27. (New) A method for detecting compositions that effect inflammation, comprising,

a) adding to a first cell culture a composition comprising a compound with an unknown effect on inflammation;

b) adding a stimulatory agent to the first cell culture and a second cell culture;

c) measuring an amount of secreted determinant of inflammation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF-α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture to the amount of determinant from the second cell culture.

B4 cont

28. (New) The method of Claim 27, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.

29. (New) The method of Claim 27, wherein the inflammation is vascular complications of diabetes, ventricular hypertrophy, atherosclerosis angiopathy, myocarditis, nephritis, arthritis, glomerulonephritis, microangiopathies, renal insuffiency and Alzheimer's disease.

30. (New) The method of Claim 27, wherein the stimulatory agent is a glycated protein.

31. (New) The stimulatory agent of Claim 30, wherein the glycated protein is G-HSA, or AGE.

32. (New) The method of Claim 27, wherein after adding the stimulatory agent, the cells are cultured for a predetermined amount of time.

33. (New) The method of Claim 27, wherein b) adding a stimulating agent to the first cell culture precedes a) the adding of a composition with unknown effect on inflammation to the first cell culture.

34. (New) The method of Claim 27, wherein a) adding a composition comprising a compound with an unknown effect on inflammation to the first cell culture and b) adding a stimulating agent to the first cell culture, occur simultaneously.